$2.36
+0.35 (+17.41%)
Open$2.03
Previous Close$2.01
Day High$2.37
Day Low$1.96
52W High$3.54
52W Low$0.76
Volume—
Avg Volume579.8K
Market Cap127.40M
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,042.4% upside
Current
$2.36
$2.36
Target
$26.96
$26.96
$18.17
$26.96 avg
$35.46
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 68.45M | 35.55M | 33.75M |
| Net Income | -13,439,175 | 3.58M | 3.41M |
| Profit Margin | -19.6% | 10.1% | 10.1% |
| EBITDA | -14,905,588 | 5.92M | 5.34M |
| Free Cash Flow | — | 3.84M | 3.54M |
| Rev Growth | — | -9.4% | +19.8% |
| Debt/Equity | — | 0.12 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |